Otolaryngol Head Neck Surg:鼻甲复位的鼻中隔成形术结果在过敏性鼻炎患者中的前瞻性研究

2019-04-17 AlexYang MedSci原创

最近,有研究人员利用验证过的结果和生活质量(QOL)调查工具对过敏性鼻炎患者和非过敏性鼻炎患者就鼻甲复位的鼻中隔成形术结果进行了比较。研究是一个前瞻性的、观察性的群体研究。研究包括了60名症状性鼻中隔偏曲连续性患者,其中30名患有过敏性鼻炎。研究进行的时间为2014年3月到2017年2月。所有的患者均经历了鼻中隔成形术和下鼻甲复位。研究人员发现,NOSE评分、EOB评分和mini-RQLQ评分在2

最近,有研究人员利用验证过的结果和生活质量(QOL)调查工具对过敏性鼻炎患者和非过敏性鼻炎患者就鼻甲复位的鼻中隔成形术结果进行了比较。

研究是一个前瞻性的、观察性的群体研究。研究包括了60名症状性鼻中隔偏曲连续性患者,其中30名患有过敏性鼻炎。研究进行的时间为2014年3月到2017年2月。所有的患者均经历了鼻中隔成形术和下鼻甲复位。研究人员发现,NOSE评分、EOB评分和mini-RQLQ评分在2个小组治疗的第3个月和第6个月均有显著的改善。结果从第3个月到第6个月均稳定。尽管mini-RQLQ在所有时间段中过敏性鼻炎患者均更高,但变化的幅度在2个小组中相当。

最后,研究人员指出,尽管过敏性鼻炎患者报道具有比非过敏性鼻炎患者更大的过敏相关的QOL损失(mini-RQLQ),但是就鼻阻塞来讲并没有影响鼻中隔成形术和鼻甲复位对其的治疗结果。更多的是,结构性鼻阻塞症状缓解能够显著的改善他们的总的生活质量。如果术前设置适当的期望,过敏性鼻炎既不是禁忌症,也不是鼻中隔成形术和鼻甲复位手术进行的障碍,并且这些患者可以合理地期待更高的术后满意度。

原始出处:

Gillman GS, Staltari GV, Chang YF et al. A Prospective Study of Outcomes of Septoplasty with Turbinate Reductions in Patients with Allergic Rhinitis. Otolaryngol Head Neck Surg. 26 Mar 2019.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2006457, encodeId=e5f9200645e40, content=<a href='/topic/show?id=924a3264381' target=_blank style='color:#2F92EE;'>#前瞻性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32643, encryptionId=924a3264381, topicName=前瞻性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5cb32500112, createdName=1508842480_96220437, createdTime=Sun Feb 09 03:52:00 CST 2020, time=2020-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044094, encodeId=e728204409487, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Tue Oct 15 00:52:00 CST 2019, time=2019-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2004718, encodeId=86b52004e18e1, content=<a href='/topic/show?id=4e8a5400816' target=_blank style='color:#2F92EE;'>#成形术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54008, encryptionId=4e8a5400816, topicName=成形术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fb6449, createdName=ZGMFX24A, createdTime=Wed Mar 25 07:52:00 CST 2020, time=2020-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1914467, encodeId=a5af191446e00, content=<a href='/topic/show?id=103f3264681' target=_blank style='color:#2F92EE;'>#前瞻性研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32646, encryptionId=103f3264681, topicName=前瞻性研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Mon Aug 19 02:52:00 CST 2019, time=2019-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047102, encodeId=814e204e10252, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Mon Nov 04 02:52:00 CST 2019, time=2019-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1604177, encodeId=a6f416041e7bc, content=<a href='/topic/show?id=edfe103399a6' target=_blank style='color:#2F92EE;'>#鼻中隔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103399, encryptionId=edfe103399a6, topicName=鼻中隔)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Fri Apr 19 04:52:00 CST 2019, time=2019-04-19, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2006457, encodeId=e5f9200645e40, content=<a href='/topic/show?id=924a3264381' target=_blank style='color:#2F92EE;'>#前瞻性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32643, encryptionId=924a3264381, topicName=前瞻性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5cb32500112, createdName=1508842480_96220437, createdTime=Sun Feb 09 03:52:00 CST 2020, time=2020-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044094, encodeId=e728204409487, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Tue Oct 15 00:52:00 CST 2019, time=2019-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2004718, encodeId=86b52004e18e1, content=<a href='/topic/show?id=4e8a5400816' target=_blank style='color:#2F92EE;'>#成形术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54008, encryptionId=4e8a5400816, topicName=成形术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fb6449, createdName=ZGMFX24A, createdTime=Wed Mar 25 07:52:00 CST 2020, time=2020-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1914467, encodeId=a5af191446e00, content=<a href='/topic/show?id=103f3264681' target=_blank style='color:#2F92EE;'>#前瞻性研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32646, encryptionId=103f3264681, topicName=前瞻性研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Mon Aug 19 02:52:00 CST 2019, time=2019-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047102, encodeId=814e204e10252, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Mon Nov 04 02:52:00 CST 2019, time=2019-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1604177, encodeId=a6f416041e7bc, content=<a href='/topic/show?id=edfe103399a6' target=_blank style='color:#2F92EE;'>#鼻中隔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103399, encryptionId=edfe103399a6, topicName=鼻中隔)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Fri Apr 19 04:52:00 CST 2019, time=2019-04-19, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2006457, encodeId=e5f9200645e40, content=<a href='/topic/show?id=924a3264381' target=_blank style='color:#2F92EE;'>#前瞻性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32643, encryptionId=924a3264381, topicName=前瞻性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5cb32500112, createdName=1508842480_96220437, createdTime=Sun Feb 09 03:52:00 CST 2020, time=2020-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044094, encodeId=e728204409487, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Tue Oct 15 00:52:00 CST 2019, time=2019-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2004718, encodeId=86b52004e18e1, content=<a href='/topic/show?id=4e8a5400816' target=_blank style='color:#2F92EE;'>#成形术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54008, encryptionId=4e8a5400816, topicName=成形术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fb6449, createdName=ZGMFX24A, createdTime=Wed Mar 25 07:52:00 CST 2020, time=2020-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1914467, encodeId=a5af191446e00, content=<a href='/topic/show?id=103f3264681' target=_blank style='color:#2F92EE;'>#前瞻性研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32646, encryptionId=103f3264681, topicName=前瞻性研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Mon Aug 19 02:52:00 CST 2019, time=2019-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047102, encodeId=814e204e10252, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Mon Nov 04 02:52:00 CST 2019, time=2019-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1604177, encodeId=a6f416041e7bc, content=<a href='/topic/show?id=edfe103399a6' target=_blank style='color:#2F92EE;'>#鼻中隔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103399, encryptionId=edfe103399a6, topicName=鼻中隔)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Fri Apr 19 04:52:00 CST 2019, time=2019-04-19, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2006457, encodeId=e5f9200645e40, content=<a href='/topic/show?id=924a3264381' target=_blank style='color:#2F92EE;'>#前瞻性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32643, encryptionId=924a3264381, topicName=前瞻性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5cb32500112, createdName=1508842480_96220437, createdTime=Sun Feb 09 03:52:00 CST 2020, time=2020-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044094, encodeId=e728204409487, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Tue Oct 15 00:52:00 CST 2019, time=2019-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2004718, encodeId=86b52004e18e1, content=<a href='/topic/show?id=4e8a5400816' target=_blank style='color:#2F92EE;'>#成形术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54008, encryptionId=4e8a5400816, topicName=成形术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fb6449, createdName=ZGMFX24A, createdTime=Wed Mar 25 07:52:00 CST 2020, time=2020-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1914467, encodeId=a5af191446e00, content=<a href='/topic/show?id=103f3264681' target=_blank style='color:#2F92EE;'>#前瞻性研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32646, encryptionId=103f3264681, topicName=前瞻性研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Mon Aug 19 02:52:00 CST 2019, time=2019-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047102, encodeId=814e204e10252, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Mon Nov 04 02:52:00 CST 2019, time=2019-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1604177, encodeId=a6f416041e7bc, content=<a href='/topic/show?id=edfe103399a6' target=_blank style='color:#2F92EE;'>#鼻中隔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103399, encryptionId=edfe103399a6, topicName=鼻中隔)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Fri Apr 19 04:52:00 CST 2019, time=2019-04-19, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2006457, encodeId=e5f9200645e40, content=<a href='/topic/show?id=924a3264381' target=_blank style='color:#2F92EE;'>#前瞻性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32643, encryptionId=924a3264381, topicName=前瞻性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5cb32500112, createdName=1508842480_96220437, createdTime=Sun Feb 09 03:52:00 CST 2020, time=2020-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044094, encodeId=e728204409487, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Tue Oct 15 00:52:00 CST 2019, time=2019-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2004718, encodeId=86b52004e18e1, content=<a href='/topic/show?id=4e8a5400816' target=_blank style='color:#2F92EE;'>#成形术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54008, encryptionId=4e8a5400816, topicName=成形术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fb6449, createdName=ZGMFX24A, createdTime=Wed Mar 25 07:52:00 CST 2020, time=2020-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1914467, encodeId=a5af191446e00, content=<a href='/topic/show?id=103f3264681' target=_blank style='color:#2F92EE;'>#前瞻性研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32646, encryptionId=103f3264681, topicName=前瞻性研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Mon Aug 19 02:52:00 CST 2019, time=2019-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047102, encodeId=814e204e10252, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Mon Nov 04 02:52:00 CST 2019, time=2019-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1604177, encodeId=a6f416041e7bc, content=<a href='/topic/show?id=edfe103399a6' target=_blank style='color:#2F92EE;'>#鼻中隔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103399, encryptionId=edfe103399a6, topicName=鼻中隔)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Fri Apr 19 04:52:00 CST 2019, time=2019-04-19, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2006457, encodeId=e5f9200645e40, content=<a href='/topic/show?id=924a3264381' target=_blank style='color:#2F92EE;'>#前瞻性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32643, encryptionId=924a3264381, topicName=前瞻性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5cb32500112, createdName=1508842480_96220437, createdTime=Sun Feb 09 03:52:00 CST 2020, time=2020-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044094, encodeId=e728204409487, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Tue Oct 15 00:52:00 CST 2019, time=2019-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2004718, encodeId=86b52004e18e1, content=<a href='/topic/show?id=4e8a5400816' target=_blank style='color:#2F92EE;'>#成形术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54008, encryptionId=4e8a5400816, topicName=成形术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fb6449, createdName=ZGMFX24A, createdTime=Wed Mar 25 07:52:00 CST 2020, time=2020-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1914467, encodeId=a5af191446e00, content=<a href='/topic/show?id=103f3264681' target=_blank style='color:#2F92EE;'>#前瞻性研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32646, encryptionId=103f3264681, topicName=前瞻性研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Mon Aug 19 02:52:00 CST 2019, time=2019-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047102, encodeId=814e204e10252, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Mon Nov 04 02:52:00 CST 2019, time=2019-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1604177, encodeId=a6f416041e7bc, content=<a href='/topic/show?id=edfe103399a6' target=_blank style='color:#2F92EE;'>#鼻中隔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103399, encryptionId=edfe103399a6, topicName=鼻中隔)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Fri Apr 19 04:52:00 CST 2019, time=2019-04-19, status=1, ipAttribution=)]

相关资讯

Allergy Asthma Immunol Res:鼻一氧化氮与鼻腔通畅和鼻症状有关

一氧化氮(NO)在上呼吸道和下呼吸道系统中是一种重要的内源性调节因子。最近,有研究人员阐释了中国成年人的鼻NO(nNO)正常范围以及内在的影响因子,并且进一步调查了鼻炎和无症状特应性人群之间的nNO水平差异以及过敏性鼻炎(AR)中诊断nNO的价值。研究包括了1000名成年人,并根据调查问卷和皮刺试验分成不同的亚群。研究发现,nNO和FeNO水平在AR患者中要比健康和无症状特应性参与者显著更高。nN

Environ Int:儿童哮喘和鼻炎与家庭潮湿相关接触相关性研究

在2010年和2012年之间,有研究人员对来自中国7个城市的40010名学龄前儿童的家庭环境与健康结果进行了观察性的研究。在研究中,他们调查了当前居住环境的6个潮湿相关的指标(可见的霉菌斑、可见潮湿污渍、潮湿衣物及/或床上用品、水渍、窗玻璃凝结和发霉气味)与早期居住环境的3个潮湿相关指标(可见的霉菌斑、窗玻璃凝结和发霉气味)与儿童哮喘和鼻炎之间的相关性。研究发现,在多水平的逻辑回归分析中,当前居住

Int Immunopharmacol:没食子酸能减轻过敏性鼻炎模型中的鼻腔炎症

过敏性鼻炎(AR)是一种过敏性鼻疾病,可以通过鼻塞、流鼻涕、打喷嚏和瘙痒来进行鉴定。1型T辅助细胞(Th1)和2型T辅助细胞(Th2)的不平衡已经被鉴定是AR的重要免疫机制。另外,17型T辅助细胞(Th17)的上调同样也能增加发展为AR的风险。没食子酸(GA)是一种多酚天然产物,可以来自于各种草药、红酒和绿茶。其具有多样的生物学功能,比如抗氧化、抗炎症、抗微生物和抗癌征等。最近,有研究人员在OVA

Allergol Immunopathol (Madr):哮喘和/或鼻炎儿童血清维生素D水平季节性变化的不可预测性分析

一些研究已经表明了季节性是维生素D(vitD)状态的一个重要确定因素。最近,有研究人员评估了哮喘和鼻炎儿童中是否在1年之内血清vitD水平的变化趋势具有差异。研究包括了92名哮喘和鼻炎儿科患者,并进行了为期1年的跟踪调查研究,他们的血清vitD水平每个季节测量一次。研究发现,在夏季结束和冬季结束时vitD的水平更高。然而,个体的季节性趋势变化多端且不可预测。如果设定在一个季节中大多数患者的变化在一

Allergy:局部过敏性鼻炎患者屋尘螨激发的支气管炎研究

超过30%的局部过敏性鼻炎(LAR)患者具有自我报道的哮喘支气管症状,但是过敏原接触与支气管症状之间的相关性还未研究。最近,有研究人员调查了是否存在与LAR相对应的支气管病变。研究人员通过临床历史、皮刺测试/血清特异性lgE(slgE)和鼻过敏原激发测试(NAPT)将患者分成LAR、过敏性鼻炎(AR)和非过敏性鼻炎(NAR)表型。总共包括了28名LAR,18名AR和19名NAR以及8名健康对照(H

Chin Med J (Engl):亚太地区哮喘和过敏性鼻炎医生调查

在中国,过敏性鼻炎(AR)和哮喘患病率在过去几十年一直在增加。由于这两种疾病经常共存,ASPAIR研究旨在评估6个亚洲国家中医生对哮喘和鼻炎共存时的观点和治疗模式。研究发现,在接受采访的医生中,约有70%的医生会定期评估其哮喘或AR患者是否有并存疾病的迹象。虽然大多数医生(>90%)意识到了哮喘与AR的共存相比单独其中一种疾病会增加患者的疾病负担,并且还需要额外的治疗,但是大多数医生(96%